Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft models with favorable pharmacokinetic and safety profiles● ZW171 induced potent preferential... | April 18, 2023
Source: marketscreener.com